In this article, we discuss the top 10 stocks in Dov Gertzulin’s portfolio. If you want to skip our detailed analysis of Gertzulin’s history, investment philosophy, and hedge fund performance, go directly to Dov Gertzulin’s Portfolio: Top 5 Stocks.
Serving as its portfolio manager, Dov Gertzulin is the founder of the New York-based investment firm, DG Capital Management, specializing in middle market opportunities across the capital structure, with a focus on distressed securities and reorganized equity. After earning his BBA from Baruch College and his M.B.A from New York University’s Stern School of Business, Gertzulin began his career in finance and asset management. Prior to establishing DG Capital Management in 2007, he served as a research analyst at JDS Capital Management. He later joined Neuberger Berman as a portfolio manager, where he co‐managed over $4 billion in assets.
Some of the most notable stocks present in the investment portfolio of DG Capital Management at the end of the second quarter of 2021 include United Therapeutics Corporation (NASDAQ:UTHR), Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) and Caesars Entertainment, Inc. (NASDAQ:CZR), among others discussed in detail below.
George Drachas The Uncomplicated Guide to Investing drachas.com
Our Methodology
With this context, let us now analyze the top 10 stocks in Dov Gertzulin’s portfolio. We looked into DG Capital Management’s 13F portfolio for the second quarter for this list.
Why should we pay attention to Dov Gertzulin’s stocks? Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 86 percentage points since March 2017. Between March 2017 and July 2021 our monthly newsletter’s stock picks returned 186.1%, vs. 100.1% for the SPY. Our stock picks outperformed the market by 86 percentage points (see the details here). That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.
Dov Gertzulin Portfolio: Top 10 Stocks
10. Brinker International, Inc. (NYSE:EAT)
DG Capital Management’s Stake Value: $15.9 million
Percentage of DG Capital Management’s 13F Portfolio: 3.45%
Number of Hedge Fund Holders: 31
Based in Texas, Brinker International, Inc. (NYSE:EAT) is one of the world’s leading restaurant companies, operating more than 1,600 restaurants in 29 countries.
As of Q2 2021, 31 hedge funds tracked by Insider Monkey have positions in Brinker International, Inc. (NYSE:EAT). The number of hedge funds that held stakes in the company remained unchanged in the first and second quarters of 2021. The hedge fund managed by Dov Gertzulin holds 258,559 shares in the company, amounting to more than $15.9 million in worth and accounting for 3.45% of the fund’s portfolio.
For the fiscal first quarter of 2022, Brinker International, Inc. (NYSE:EAT) reported an EPS of $0.34, falling short of estimates by $0.37. On the other hand, the company’s revenue for the quarter came in at $876.4 million, crossing market estimates by $0.18 million.
On October 22, Raymond James analyst Brian Vaccaro lowered his price target on Brinker International, Inc. (NYSE:EAT) to $60 from $67.50, and kept an Outperform rating on the shares.
9. Dine Brands Global, Inc. (NYSE:DIN)
DG Capital Management’s Stake Value: $16.85 million
Percentage of DG Capital Management’s 13F Portfolio: 3.63%
Number of Hedge Fund Holders: 28
Dine Brands Global, Inc. (NYSE:DIN) is an American food and dining company based in California that manages and operates the famous brands, Applebee’s and IHOP.
Dine Brands Global, Inc. (NYSE: DIN) reported solid earnings in Q3 2021, with earnings per share at $1.55, crossing estimates by $0.19. The company declared revenue of $228.72 million, beating predictions by $5.25 million.
As of Q2 2021, 28 hedge funds have positions in Dine Brands Global, Inc. (NYSE:DIN), the same as the previous quarter. DG Capital Management reported owning 188,824 shares in the company, worth more than $16.85 million, representing 3.63% of the investment firm’s portfolio.
On November 5, Wedbush analyst Nick Setyan raised the price target on Dine Brands Global, Inc. (NYSE:DIN) to $105 from $97, and kept an Outperform rating on the shares of the company.
Similar to United Therapeutics Corporation (NASDAQ:UTHR), Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) and Caesars Entertainment, Inc. (NASDAQ:CZR), Dine Brands Global, Inc. (NYSE:DIN) is a stock investors are paying attention to.
8. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)
DG Capital Management’s Stake Value: $17.5 million
Percentage of DG Capital Management’s 13F Portfolio: 3.78%
Number of Hedge Fund Holders: 56
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is a biopharmaceutical company engaged in the research and development of medicines for rheumatic and other rare diseases.
The company posted its quarterly earnings report for the third quarter of 2021 on November 3, reporting earnings per share of $1.75, beating estimates by $0.21. The revenue over the period was reported at around $1.04 billion, an increase of 62.94% on a year-over-year basis.
According to the Q2 13F Filings, Dov Gertzulin’s DG Capital Management held over 187,314 shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), worth more than $17.5 million, accounting for 3.78% of the fund’s investment portfolio. At the end of the second quarter of 2021, 56 hedge funds in the database of Insider Monkey held stakes worth $4.3 billion in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). This is compared to 48 hedge funds in the previous quarter that held stakes worth roughly $4.1 billion.
On October 6, Jefferies analyst Akash Tewari assumed coverage of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) with a Buy rating and $132 price target.
Carillon Tower Advisers, in their Q1 2021 investor letter, explains the position of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)’s Tepezza product. Here is what the fund said:
“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”
7. Caesars Entertainment, Inc. (NASDAQ:CZR)
DG Capital Management’s Stake Value: $18.18 million
Percentage of DG Capital Management’s 13F Portfolio: 3.92%
Number of Hedge Fund Holders: 73
Formerly known as Eldorado Resorts, Inc., Caesars Entertainment, Inc. (NASDAQ:CZR) is among the world’s largest diversified hotel and casino entertainment companies.
Dov Gertzulin of DG Capital Management is one of the leading stakeholders of Caesars Entertainment, Inc. (NASDAQ:CZR), with 175,250 shares worth over $18.18 million as of the end of the second quarter, according to the data tracked by Insider Monkey.
At the end of the second quarter of 2021, 73 hedge funds in the database of Insider Monkey held stakes worth $1.83 billion in Caesars Entertainment, Inc. (NASDAQ:CZR) down from 76 in the preceding quarter worth $1.52 billion.
On October 20, Morgan Stanley analyst Thomas Allen raised his price target on Caesars Entertainment, Inc. (NASDAQ:CZR) to $138 from $127, and kept an Overweight rating on the shares of the company.
6. Bloomin’ Brands, Inc. (NASDAQ:BLMN)
DG Capital Management’s Stake Value: $18.87 million
Percentage of DG Capital Management’s 13F Portfolio: 4.07%
Number of Hedge Fund Holders: 36
Bloomin’ Brands, Inc. (NASDAQ:BLMN) is a Florida-based restaurant holding company that owns and operates over 1,450 restaurants in 47 states. The company manages several American casual dining restaurant chains such as Outback Steakhouse and Bonefish Grill.
On November 3, Raymond James analyst Brian Vaccaro kept a Strong Buy rating on Bloomin’ Brands, Inc. (NASADQ:BLMN), alongside a $30 price target on its shares.
DG Capital Management currently holds 695,367 shares in the company, worth $18.87 million, accounting for 4.07% of the investment firms’ portfolio value.
In addition to, United Therapeutics Corporation (NASDAQ:UTHR), Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) and Caesars Entertainment, Inc. (NASDAQ:CZR), Bloomin’ Brands, Inc. (NASDAQ:BLMN) is a notable stock to invest in.
Click to continue reading and see Dov Gertzulin’s Portfolio: Top 5 Stocks.
Suggested articles:
- 15 Best Cities For Singles Over 40
- 15 Best Blue Chip Stocks To Buy Now
- 15 Largest Electronics Companies in the World
Disclosure: None. Dov Gertzulin’s Portfolio: Top 10 Stocks is originally published on Insider Monkey.
